Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB (Repeat Dosing) Trial of Second Dose Oncolytic HSV Administered Intratumorally in Patients With Recurrent Malignant Glioma.

NCT06193174 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT06193174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06193174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB (Repeat Dosing) Trial of Second Dose Oncolytic HSV Administered Intratumorally in Patients With Recurrent Malignant Glioma.
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Terminated
Start date
June 21, 2024
Completion date
March 7, 2025
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma of brain, glioblastoma multiforme of brain, gliosarcoma of brain, recurrent malignant glioma